0.00Open0.00Pre Close0 Volume0 Open Interest8.00Strike Price0.00Turnover517.55%IV28.74%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.1166Delta0.0520Gamma44.90Leverage Ratio-0.2197Theta-0.0001Rho-5.23Eff Leverage0.0014Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet